Vaxart (VXRT) to Release Earnings on Wednesday

Vaxart (NASDAQ:VXRT) is scheduled to announce its earnings results after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Vaxart (NASDAQ:VXRT) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Vaxart had a negative return on equity of 114.19% and a negative net margin of 543.21%. The business had revenue of $6.40 million for the quarter, compared to the consensus estimate of $65.70 million. During the same quarter in the previous year, the company posted ($0.16) earnings per share. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vaxart Stock Down 0.3 %

Vaxart stock opened at $0.72 on Friday. The company has a market capitalization of $127.75 million, a PE ratio of -1.57 and a beta of 0.70. Vaxart has a 12-month low of $0.52 and a 12-month high of $1.54. The firm’s fifty day moving average is $0.83 and its 200 day moving average is $0.77.

Analyst Upgrades and Downgrades

Separately, Oppenheimer began coverage on Vaxart in a research note on Thursday, August 15th. They issued an “outperform” rating and a $4.00 target price for the company.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.